The role of CLU in molecular pathogenesis of alzheimers disease

Active Grant Awarded

Award ID
R56AG100407
Recipient
Awarding agency
Obligated
$798,749

Award facts

Assistance listing
93.866 Aging Research
Completion date 18% complete
Place of performance
Phoenix, AZ 85004, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through the National Institute on Aging, awarded The Translational Genomics Research Institute, doing business as Tgen Research Institute, a grant with $798,749 obligated on September 18, 2026, under the Aging Research program (CFDA 93.866).

The award funds a project on clusterin (CLU), a gene strongly linked to Alzheimer's disease risk, and its role in the molecular pathogenesis of the disease. The research team, which created a humanized mouse model that controls human CLU expression in different brain cell types, will pursue three aims: defining which brain cell types drive CLU's effects on plaque and vessel pathology through cell-specific gene deletion; uncovering molecular signatures linked to CLU expression using single-cell and spatial transcriptomics; and testing a nanobody-based therapeutic that targets CLU to remove amyloid plaques while sparing effects on blood vessels.

Performance runs from the award date through an ultimate completion date of August 31, 2027, with place of performance in Phoenix, Arizona 85004. The Aging Research program supports biomedical, social, and behavioral research on the aging process and its diseases, with a particular emphasis on preventing and treating Alzheimer's disease and related dementias.

Description

Abstract
Alzheimer's disease (ad) affects over six million americans and is marked by the buildup of toxic proteins in the brain that damage neurons and lead to memory loss and cognitive decline. While current therapies targeting amyloid plaques have shown some promise, they are limited by serious side effects, including brain swelling and bleeding, known as amyloid related imaging abnormalities (ARIA). The molecular cascade of events that lead to ARIA are unknown, but we do know that cerebral amyloid angiopathy (CAA) is the site of these events as well as other hemorrhagic events even in untreated alzheimer's disease patients. These vascular complications have stalled therapeutic progress and highlight the urgent need for safer, more precise approaches and a better overall understanding of the pathogenesis of CAA and associated sequelae. This project focuses on clusterin (CLU), a gene strongly linked to ad risk but far less studied than the well-known apoe gene. Both genes encode apolipoproteins that influence how and where amyloid builds up in the brain. Our research team has created a novel humanized mouse model that allows precise control over human CLU expression in different brain cell types. Our central hypothesis is that CLU produced by astrocytes controls early amyloid formation, while CLU embedded within plaques can be safely targeted after disease onset to clear amyloid without vascular side effects. To test this, the team will pursue three specific aims: (1) define which brain cell types are responsible for CLU's effects on plaque and vessel pathology using cell-specific gene deletion, (2) uncover molecular signatures linked to CLU expression through state-of-the-art genomic techniques including single-cell and spatial transcriptomics, and (3) test a new nanobody-based therapeutic that targets CLU to remove amyloid plaques while sparing effects on blood vessels. This work represents a novel and highly innovative strategy to address a major challenge in ad therapeutics. By targeting a previously underexplored yet genetically validated risk gene, this project could lead to safer immunotherapies and new insights into how different brain cell types shape disease progression. If successful, IT will lay the groundwork for next-generation ad treatments that are both effective and safe.

Quick answers

Who received award R56AG100407?

R56AG100407 was awarded to The Translational Genomics Research Institute by National Institute on Aging (National Institutes of Health) on September 18, 2026.

How much is award R56AG100407 worth?

$798,749 has been obligated on R56AG100407.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award